Triple-negative breast cancer (TNBC) is a disease characterized by the lack of estrogen receptor (ER) and progesterone receptor (PgR) expression as well as human epidermal growth factor receptor 2 (HER2) amplification, and accounts for 10–20% of all breast cancers. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.